(GILD) Gilead Sciences Terminates Letairis Phase III Trial
Gilead Sciences Inc.(GILD) recently announced that it will terminate its phase III trial (ARTEMIS-IPF) studying Letairis (ambrisentan) for the treatment of idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. The study’s Data Monitoring Committee (DMC) had conducted an interim analysis of the efficacy and safety data of the trial. The data was also reviewed [...] (GILD) Gilead Sciences Terminates Letairis Phase III Trial
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here

Portions of this content may be copy written by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. SmartReadMX and other related related technologies used to produce content for this service are covered by US Patents numbers 7,865,496, 7,856,390, and 7,716,116.